Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Tandem Diabetes Care (TNDM) over the last 14 years, with Q3 2025 value amounting to $96.9 million.

  • Tandem Diabetes Care's Other Accumulated Expenses rose 15283.02% to $96.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.9 million, marking a year-over-year increase of 15283.02%. This contributed to the annual value of $49.3 million for FY2024, which is 7325.56% up from last year.
  • Per Tandem Diabetes Care's latest filing, its Other Accumulated Expenses stood at $96.9 million for Q3 2025, which was up 15283.02% from $100.0 million recorded in Q2 2025.
  • In the past 5 years, Tandem Diabetes Care's Other Accumulated Expenses ranged from a high of $100.0 million in Q2 2025 and a low of $18.3 million during Q2 2021
  • Its 5-year average for Other Accumulated Expenses is $39.5 million, with a median of $30.1 million in 2023.
  • As far as peak fluctuations go, Tandem Diabetes Care's Other Accumulated Expenses crashed by 294.29% in 2023, and later soared by 20263.04% in 2025.
  • Quarter analysis of 5 years shows Tandem Diabetes Care's Other Accumulated Expenses stood at $23.4 million in 2021, then grew by 25.38% to $29.3 million in 2022, then fell by 2.94% to $28.5 million in 2023, then skyrocketed by 73.26% to $49.3 million in 2024, then skyrocketed by 96.47% to $96.9 million in 2025.
  • Its Other Accumulated Expenses stands at $96.9 million for Q3 2025, versus $100.0 million for Q2 2025 and $91.8 million for Q1 2025.